{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:55:24Z","timestamp":1769630124902,"version":"3.49.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R01 DE033909"],"award-info":[{"award-number":["R01 DE033909"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["T32GM153123"],"award-info":[{"award-number":["T32GM153123"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jpet.2025.103725","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:53:38Z","timestamp":1758819218000},"page":"103725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Chemokine-chemokine receptor networks in conventional type I dendritic cells: an opportunity to prime and boost anticancer immunity"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1804-9673","authenticated-orcid":false,"given":"Ning","family":"Kuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-756X","authenticated-orcid":false,"given":"Cheyanne Kristen","family":"Shinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-9547","authenticated-orcid":false,"given":"Shiruyeh","family":"Schokrpur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Idoyaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy","family":"Handel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-4482","authenticated-orcid":false,"given":"Jorge Silvio","family":"Gutkind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jpet.2025.103725_bib1","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/s41423-024-01167-5","article-title":"The role of plasmacytoid dendritic cells (pDCs) in immunity during viral infections and beyond","volume":"21","author":"Ngo","year":"2024","journal-title":"Cell Mol Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jpet.2025.103725_bib3","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00018-022-04219-z","article-title":"Type I interferon-mediated tumor immunity and its role in immunotherapy","volume":"79","author":"Yu","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"10.1016\/j.jpet.2025.103725_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.jpet.2025.103725_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","article-title":"Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses","volume":"56","author":"Bayerl","year":"2023","journal-title":"Immunity"},{"issue":"9","key":"10.1016\/j.jpet.2025.103725_bib6","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1158\/1078-0432.CCR-23-3477","article-title":"Targeting dendritic cell dysfunction to circumvent anti-PD1 resistance in head and neck cancer","volume":"30","author":"Saito","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jpet.2025.103725_bib7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"5904","key":"10.1016\/j.jpet.2025.103725_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jpet.2025.103725_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","article-title":"Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells","volume":"6","author":"S\u00e1nchez-Paulete","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.jpet.2025.103725_bib10","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1038\/s41467-022-31941-w","article-title":"Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC","volume":"13","author":"Saddawi-Konefka","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib11","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240776","article-title":"The XCL1-XCR1 axis supports intestinal tissue residency and antitumor immunity","volume":"222","author":"Ferry","year":"2025","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpet.2025.103725_bib12","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","article-title":"Chemokines and chemokine receptors: positioning cells for host defense and immunity","volume":"32","author":"Griffith","year":"2014","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103725_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.jpet.2025.103725_bib14","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1021\/acs.biochem.5b01329","article-title":"Examination of glycosaminoglycan binding sites on the XCL1 dimer","volume":"55","author":"Fox","year":"2016","journal-title":"Biochemistry"},{"issue":"13","key":"10.1016\/j.jpet.2025.103725_bib15","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1073\/pnas.0709518105","article-title":"Interconversion between two unrelated protein folds in the lymphotactin native state","volume":"105","author":"Tuinstra","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"10.1016\/j.jpet.2025.103725_bib16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2405732121","article-title":"Molecular basis for chemokine recognition and activation of XCR1","volume":"121","author":"Zhang","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.jpet.2025.103725_bib17","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib18","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jpet.2025.103725_bib19","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3389\/fimmu.2019.01014","article-title":"Beyond cDC1: emerging roles of DC crosstalk in cancer immunity","volume":"10","author":"Noubade","year":"2019","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103725_bib20","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","article-title":"The role of type 1 conventional dendritic cells in cancer immunity","volume":"4","author":"B\u00f6ttcher","year":"2018","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.jpet.2025.103725_bib21","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.immuni.2020.05.005","article-title":"Transcriptional networks driving dendritic cell differentiation and function","volume":"52","author":"Nutt","year":"2020","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.jpet.2025.103725_bib22","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/eji.201040498","article-title":"From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets","volume":"40","author":"Guilliams","year":"2010","journal-title":"Eur J Immunol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103725_bib23","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1002\/embj.201488027","article-title":"Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming","volume":"33","author":"Dalod","year":"2014","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.jpet.2025.103725_bib24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev-immunol-090122-041105","article-title":"Ontogeny and function of plasmacytoid dendritic cells","volume":"42","author":"Adams","year":"2024","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"10.1016\/j.jpet.2025.103725_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025660","article-title":"Batf3-dependent CD11b(low\/-) peripheral dendritic cells are GM-CSF-independent and are not required for Th cell priming after subcutaneous immunization","volume":"6","author":"Edelson","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1084\/jem.20091627","article-title":"Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells","volume":"207","author":"Edelson","year":"2010","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.immuni.2011.08.008","article-title":"CD8alpha(+) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites","volume":"35","author":"Mashayekhi","year":"2011","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.jpet.2025.103725_bib28","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.immuni.2013.04.011","article-title":"IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses","volume":"38","author":"Schlitzer","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2013.08.029","article-title":"CD301b(+) dermal dendritic cells drive T helper 2 cell-mediated immunity","volume":"39","author":"Kumamoto","year":"2013","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.immuni.2012.10.016","article-title":"Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain T helper 2 cell-mediated immunity to house dust mite allergen","volume":"38","author":"Plantinga","year":"2013","journal-title":"Immunity"},{"issue":"6287","key":"10.1016\/j.jpet.2025.103725_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaf4822","article-title":"IgA production requires B cell interaction with subepithelial dendritic cells in Peyer's patches","volume":"352","author":"Reboldi","year":"2016","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jpet.2025.103725_bib32","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.immuni.2013.03.009","article-title":"IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation","volume":"38","author":"Persson","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jpet.2025.103725_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41423-021-00741-5","article-title":"Dendritic cells in cancer immunology","volume":"19","author":"Murphy","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"13","key":"10.1016\/j.jpet.2025.103725_bib34","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1084\/jem.20091756","article-title":"The origin and development of nonlymphoid tissue CD103+ DCs","volume":"206","author":"Ginhoux","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jpet.2025.103725_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"6335","key":"10.1016\/j.jpet.2025.103725_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah4573","article-title":"Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors","volume":"356","author":"Villani","year":"2017","journal-title":"Science"},{"issue":"6342","key":"10.1016\/j.jpet.2025.103725_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/science.aag3009","article-title":"Mapping the human DC lineage through the integration of high-dimensional techniques","volume":"356","author":"See","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103725_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1146\/annurev-immunol-032713-120204","article-title":"Transcriptional control of dendritic cell development","volume":"34","author":"Murphy","year":"2016","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib39","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","article-title":"Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition","volume":"44","author":"Salmon","year":"2016","journal-title":"Immunity"},{"issue":"24","key":"10.1016\/j.jpet.2025.103725_bib40","doi-asserted-by":"crossref","first-page":"16693","DOI":"10.1074\/jbc.M709923200","article-title":"CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes","volume":"283","author":"Huysamen","year":"2008","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib41","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.immuni.2012.03.009","article-title":"The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments","volume":"36","author":"Zhang","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.jpet.2025.103725_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13720","article-title":"The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity","volume":"7","author":"Laoui","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jpet.2025.103725_bib43","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.celrep.2016.05.025","article-title":"Distinct transcriptional programs control cross-priming in classical and monocyte-derived dendritic cells","volume":"15","author":"Brise\u00f1o","year":"2016","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.jpet.2025.103725_bib44","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.immuni.2011.08.013","article-title":"Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine","volume":"35","author":"Lewis","year":"2011","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jpet.2025.103725_bib45","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1189\/jlb.0711384","article-title":"Dendritic cell-associated lectin 2 (DCAL2) defines a distinct CD8alpha- dendritic cell subset","volume":"91","author":"Kasahara","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib46","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","article-title":"Transcriptional basis of mouse and human dendritic cell heterogeneity","volume":"179","author":"Brown","year":"2019","journal-title":"Cell"},{"issue":"18","key":"10.1016\/j.jpet.2025.103725_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aam9169","article-title":"Migratory CD11b(+) conventional dendritic cells induce T follicular helper cell-dependent antibody responses","volume":"2","author":"Krishnaswamy","year":"2017","journal-title":"Sci Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib48","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.immuni.2013.08.028","article-title":"Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells","volume":"39","author":"Gao","year":"2013","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.jpet.2025.103725_bib49","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.immuni.2023.07.001","article-title":"Dendritic cell type 3 arises from Ly6C(+) monocyte-dendritic cell progenitors","volume":"56","author":"Liu","year":"2023","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib50","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.immuni.2020.06.002","article-title":"Transcriptional and functional analysis of CD1c(+) human dendritic cells identifies a CD163(+) subset priming CD8(+)CD103(+) T cells","volume":"53","author":"Bourdely","year":"2020","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jpet.2025.103725_bib51","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1158\/2326-6066.CIR-13-0102","article-title":"Dendritic cells: master regulators of the immune response","volume":"1","author":"Mellman","year":"2013","journal-title":"Cancer Immunol Res"},{"issue":"6673","key":"10.1016\/j.jpet.2025.103725_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/32588","article-title":"Dendritic cells and the control of immunity","volume":"392","author":"Banchereau","year":"1998","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1084\/jem.182.2.389","article-title":"Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products","volume":"182","author":"Sallusto","year":"1995","journal-title":"J Exp Med"},{"issue":"103","key":"10.1016\/j.jpet.2025.103725_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf4726","article-title":"Architects of immunity: how dendritic cells shape CD8(+) T cell fate in cancer","volume":"10","author":"Bhandarkar","year":"2025","journal-title":"Sci Immunol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib55","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jpet.2025.103725_bib56","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.jpet.2025.103725_bib57","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jpet.2025.103725_bib58","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20211519","article-title":"DCs at the center of help: origins and evolution of the three-cell-type hypothesis","volume":"219","author":"Wu","year":"2022","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.jpet.2025.103725_bib59","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/nri2173","article-title":"Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting","volume":"7","author":"Tacken","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jpet.2025.103725_bib60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fimmu.2014.00165","article-title":"Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets","volume":"5","author":"Wimmers","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpet.2025.103725_bib61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2019.00009","article-title":"Are conventional type 1 dendritic cells critical for protective antitumor immunity and how?","volume":"10","author":"Cancel","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103725_bib62","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231717","article-title":"CD301b+ monocyte-derived dendritic cells mediate resistance to radiotherapy","volume":"222","author":"Tadepalli","year":"2025","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jpet.2025.103725_bib63","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.immuni.2013.10.004","article-title":"Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin","volume":"39","author":"Tamoutounour","year":"2013","journal-title":"Immunity"},{"issue":"12","key":"10.1016\/j.jpet.2025.103725_bib64","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.celrep.2018.05.068","article-title":"Notch signaling facilitates in vitro generation of cross-presenting classical dendritic cells","volume":"23","author":"Kirkling","year":"2018","journal-title":"Cell Rep"},{"issue":"8","key":"10.1016\/j.jpet.2025.103725_bib65","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s43018-022-00418-6","article-title":"Cancer vaccines: the next immunotherapy frontier","volume":"3","author":"Lin","year":"2022","journal-title":"Nat Cancer"},{"issue":"12","key":"10.1016\/j.jpet.2025.103725_bib66","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1016\/j.celrep.2015.11.053","article-title":"Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling","volume":"13","author":"Tang","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.jpet.2025.103725_bib67","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jpet.2025.103725_bib68","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3389\/fimmu.2018.02030","article-title":"Radiation and local anti-CD40 generate an effective in situ vaccine in preclinical models of pancreatic cancer","volume":"9","author":"Yasmin-Karim","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103725_bib69","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-15-1456","article-title":"STING promotes the growth of tumors characterized by low antigenicity via IDO activation","volume":"76","author":"Lemos","year":"2016","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.jpet.2025.103725_bib70","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.4049\/jimmunol.1300097","article-title":"Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid","volume":"190","author":"Conlon","year":"2013","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.jpet.2025.103725_bib71","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","article-title":"Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity","volume":"26","author":"Broz","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.jpet.2025.103725_bib72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","article-title":"Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells","volume":"26","author":"Ruffell","year":"2014","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.jpet.2025.103725_bib73","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41590-018-0145-8","article-title":"Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific","volume":"19","author":"Michea","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jpet.2025.103725_bib74","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.3389\/fimmu.2018.02775","article-title":"A highly active form of XCL1\/lymphotactin functions as an effective adjuvant to recruit cross-presenting dendritic cells for induction of effector and memory CD8(+) T cells","volume":"9","author":"Matsuo","year":"2018","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.jpet.2025.103725_bib75","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/ijc.34874","article-title":"Intratumoral delivery of a highly active form of XCL1 enhances antitumor CTL responses through recruitment of CXCL9-expressing conventional type-1 dendritic cells","volume":"154","author":"Kamei","year":"2024","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2025.103725_bib76","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41598-018-38080-7","article-title":"Dendritic cell targeted Ccl3- and Xcl1-fusion DNA vaccines differ in induced immune responses and optimal delivery site","volume":"9","author":"Lys\u00e9n","year":"2019","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.jpet.2025.103725_bib77","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/s41590-023-01529-7","article-title":"The GPCR-Galpha(s)-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure","volume":"24","author":"Wu","year":"2023","journal-title":"Nat Immunol"},{"issue":"4","key":"10.1016\/j.jpet.2025.103725_bib78","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004309","article-title":"Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion","volume":"10","author":"Le Gall","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jpet.2025.103725_bib79","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1158\/0008-5472.CAN-06-3963","article-title":"Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation","volume":"67","author":"Bharadwaj","year":"2007","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.jpet.2025.103725_bib80","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41571-023-00811-9","article-title":"Targeting cancer with mRNA-lipid nanoparticles: key considerations and future prospects","volume":"20","author":"Kon","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103725_bib81","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41467-024-44787-1","article-title":"Tumour-retained activated CCR7(+) dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity","volume":"15","author":"Lee","year":"2024","journal-title":"Nat Commun"},{"issue":"7813","key":"10.1016\/j.jpet.2025.103725_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2326-5","article-title":"Author Correction: A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"582","author":"Maier","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jpet.2025.103725_bib83","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.immuni.2021.10.020","article-title":"Type I interferon activates MHC class I-dressed CD11b(+) conventional dendritic cells to promote protective anti-tumor CD8(+) T cell immunity","volume":"55","author":"Duong","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.jpet.2025.103725_bib84","doi-asserted-by":"crossref","unstructured":"Shinn CK, Saddawi-Konefka R, Salanga CL, Schokrpur S, Gutkind JS, Handel TM. Activating the CXCR3\/CXCL10 pathway overrides tumor immune suppression by enhancing immune trafficking and effector cell priming in head and neck squamous cell carcinoma. Preprint. Posted online 2025 May 6. bioRxiv 2025.04.24.650529. https:\/\/doi.org\/10.1101\/2025.04.24.650529.","DOI":"10.1101\/2025.04.24.650529"},{"issue":"11","key":"10.1016\/j.jpet.2025.103725_bib85","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1158\/0008-5472.CAN-16-2913","article-title":"Targeting autocrine CCL5-CCR5 axis reprograms immunosuppressive myeloid cells and reinvigorates antitumor immunity","volume":"77","author":"Ban","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2025.103725_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216635","article-title":"A novel antagonist of the CCL5\/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation","volume":"583","author":"Chen","year":"2024","journal-title":"Cancer Lett"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525402389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T08:19:27Z","timestamp":1764058767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525402389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":86,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0022356525402389"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103725","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemokine-chemokine receptor networks in conventional type I dendritic cells: an opportunity to prime and boost anticancer immunity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103725"}}